Saturday, July 22, 2017 3:53:42 PM
Merck's Keytruda speeds its I-O market-share grab as Bristol-Myers' Opdivo declines
by Carly Helfand | Jul 20, 2017 10:21am
The latest immuno-oncology market-share numbers are out, and they show that Merck & Co.’s Keytruda is not only gaining on Bristol-Myers Squibb archrival Opdivo, but it’s picked up the pace, too.
Over the course of June, Keytruda’s share increased by four percentage points to 32% “at the expense of” Opdivo, Leerink Partners analyst Seamus Fernandez wrote in a Wednesday note to clients, citing sales data from Symphony Health.
That data suggests “a greater month-over-month improvement for Keytruda than in months past,” he added. Bristol-Myers' overall I-O share, which includes Yervoy’s piece of the pie, dropped to 61% from 64%.
RELATED: The top 15 best-selling cancer drugs in 2022 - Keytruda
Now approved for a half-dozen cancer types, Opdivo jumped to an early I-O lead after leapfrogging first-to-market Keytruda with its quick lung cancer approval, and it still leads with 46% of the market. But Keytruda has blown past it in the all-important lung cancer space. Merck’s contender has racked up both monotherapy and combo frontline approvals, while Bristol-Myers'—which has already flopped as a monotherapy in previously untreated patients—likely won’t even have its combo data until early next year.
Keytruda has gone on a recent approval spree, too, adding a nod in microsatellite instability-high cancer, netting a bladder cancer green light and bagging a priority review in stomach cancer.
RELATED: With ASCO data tallied, Bristol-Myers loses ground to Merck in I-O field
That’s not to say Opdivo hasn’t chalked up regulatory wins of its own. For one, the med snagged a priority review in liver cancer in May. But lately, new Keytruda data has prompted industry watchers to ask whether Bristol is “falling behind”; in a post-ASCO article, Barron’s wrote that “in the near-term the fight is uphill” for the New Jersey drugmaker.
Meanwhile, the two are hardly alone on the immuno-oncology front. Bristol-Myers' Yervoy, the first-ever approved immunotherapy, still holds a 15% piece of the pie, Fernandez said, good for the No. 3 spot. Roche’s Tecentriq, first approved last May in bladder cancer, “has remained steady at 7% market share since the beginning of 2017,” he wrote, while Bavencio and Imfinzi—brand-new meds from the Pfizer-Merck KGaA team and AstraZeneca, respectively—have so far “achieved only a nominal share.”
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent NHWK News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/07/2024 04:15:18 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/03/2024 08:00:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/03/2024 11:18:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2024 12:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2024 12:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2024 12:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2024 09:00:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:52:07 PM
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 03/13/2024 10:17:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 10:01:13 AM
- Scorpius Holdings, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 03/12/2024 09:00:59 PM
- Scorpius Holdings, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 03/08/2024 05:20:00 AM
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/07/2024 09:18:08 PM
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:34:04 PM
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:00:09 PM
- NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:30:14 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:09 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM